PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33061517-1	2020	Purpose: To assess the safety, efficacy and prognostic impact of clinical factors related to lenvatinib treatment in Child-Pugh class A (CP-A) and class B (CP-B) patients with unresectable hepatocellular carcinoma (u-HCC).	lenvatinib	93-103	carboxypeptidase A1	Homo sapiens	117-135	
33061517-1	2020	Purpose: To assess the safety, efficacy and prognostic impact of clinical factors related to lenvatinib treatment in Child-Pugh class A (CP-A) and class B (CP-B) patients with unresectable hepatocellular carcinoma (u-HCC).	lenvatinib	93-103	carboxypeptidase A1	Homo sapiens	137-141	
33061517-5	2020	Frequency of lenvatinib-related adverse events, including decreased appetite (P=0.034), diarrhea (P=0.040), elevated serum bilirubin (P=0.016) and vomiting (P=0.009), were higher in CP-B than in CP-A patients.	lenvatinib	13-23	carboxypeptidase A1	Homo sapiens	195-199	
26500236-11	2016	CONCLUSIONS: Lenvatinib (12 mg once daily) demonstrated preliminary efficacy with manageable toxicity and is the recommended dose for phase II studies in patients with HCC and CP-A.	lenvatinib	13-23	carboxypeptidase A1	Homo sapiens	176-180